5.47
-0.01
(-0.27%)
As of 12:32:10 PM EDT. Market Open.
Research Analysis
Earnings Estimate
| Currency in USD | Current Qtr. (Mar 2025) | Next Qtr. (Jun 2025) | Current Year (2025) | Next Year (2026) |
|---|---|---|---|---|
| No. of Analysts | -- | -- | -- | -- |
| Avg. Estimate | 0 | 0 | 0 | 0 |
| Low Estimate | 0 | 0 | 0 | 0 |
| High Estimate | 0 | 0 | 0 | 0 |
| Year Ago EPS | -- | -- | -- | -- |
Revenue Estimate
| Currency in USD | Current Qtr. (Mar 2025) | Next Qtr. (Jun 2025) | Current Year (2025) | Next Year (2026) |
|---|---|---|---|---|
| No. of Analysts | 3 | 3 | 3 | 3 |
| Avg. Estimate | 4.44M | 10.01M | 150.63M | 194.19M |
| Low Estimate | -- | 5M | 33.28M | 98M |
| High Estimate | 8.32M | 16.7M | 220.6M | 293.78M |
| Year Ago Sales | 697k | 282k | 33.28M | 150.63M |
| Sales Growth (year/est) | 537.02% | 3,448.46% | 352.62% | 28.92% |
Earnings History
| Currency in USD | 3/31/2024 | 6/30/2024 | 9/30/2024 | 12/31/2024 |
|---|---|---|---|---|
| EPS Est. | -0.41 | -0.4 | -0.52 | -0.56 |
| EPS Actual | -0.77 | -0.76 | -0.55 | -0.5 |
| Difference | -0.36 | -0.36 | -0.03 | 0.06 |
| Surprise % | -88.30% | -90.00% | -4.76% | 10.71% |
EPS Trend
| Currency in USD | Current Qtr. (Mar 2025) | Next Qtr. (Jun 2025) | Current Year (2025) | Next Year (2026) |
|---|---|---|---|---|
| Current Estimate | 0 | 0 | 0 | 0 |
| 7 Days Ago | 0 | 0 | 0 | 0 |
| 30 Days Ago | 0 | 0 | 0 | 0 |
| 60 Days Ago | 0 | 0 | 0 | 0 |
| 90 Days Ago | 0 | 0 | 0 | 0 |
EPS Revisions
| Currency in USD | Current Qtr. (Mar 2025) | Next Qtr. (Jun 2025) | Current Year (2025) | Next Year (2026) |
|---|---|---|---|---|
| Up Last 7 Days | -- | -- | -- | -- |
| Up Last 30 Days | -- | -- | -- | -- |
| Down Last 7 Days | -- | -- | -- | -- |
| Down Last 30 Days | -- | -- | -- | -- |
Growth Estimates
| Current Qtr. | Next Qtr. | Current Year | Next Year | |
|---|---|---|---|---|
| MGTX | -- | -- | -- | -- |
| S&P 500 | 6.76% | 5.73% | 9.19% | 14.14% |
Upgrades & Downgrades
| Maintains | RBC Capital: Outperform to Outperform | 3/17/2025 |
| Maintains | Chardan Capital: Buy to Buy | 2/24/2025 |
| Maintains | Chardan Capital: Buy to Buy | 11/18/2024 |
| Maintains | RBC Capital: Outperform to Outperform | 11/14/2024 |
| Maintains | RBC Capital: Outperform to Outperform | 8/13/2024 |
| Maintains | Chardan Capital: Buy to Buy | 7/31/2024 |
Related Tickers
STOK Stoke Therapeutics, Inc.
7.67
+1.46%
QURE uniQure N.V.
9.31
+1.53%
ATYR aTyr Pharma, Inc.
2.9900
-0.66%
PRTA Prothena Corporation plc
9.47
-4.78%
ANAB AnaptysBio, Inc.
17.92
+0.31%
GLUE Monte Rosa Therapeutics, Inc.
4.4750
+1.47%
IMCR Immunocore Holdings plc
27.16
+0.87%
PVLA Palvella Therapeutics, Inc.
25.09
+2.66%
UPB Upstream Bio, Inc.
7.95
+4.90%
JANX Janux Therapeutics, Inc.
28.48
-1.62%